Li D, Liang T, Hutchins LE, et al. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. J ImmunoTher Cancer 2024;12:e008989. doi: 10.1136/jitc-2024-008989
This article has been corrected since it was first published. In figure 4I, the CD19+NT-I7 treatment group, the first and second tumor samples from the left were mistakenly duplicated. The first sample has now been replaced with the correct tumor sample. The corrected version of figure 4I is shown below.
